206 related articles for article (PubMed ID: 8783690)
1. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
Davidson RN; di Martino L; Gradoni L; Giacchino R; Gaeta GB; Pempinello R; Scotti S; Cascio A; Castagnola E; Maisto A; Gramiccia M; di Caprio D; Wilkinson RJ; Bryceson AD
Clin Infect Dis; 1996 Jun; 22(6):938-43. PubMed ID: 8783690
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions.
Seaman J; Boer C; Wilkinson R; de Jong J; de Wilde E; Sondorp E; Davidson R
Clin Infect Dis; 1995 Jul; 21(1):188-93. PubMed ID: 7578729
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
6. Treatment of visceral leishmaniasis in children with liposomal amphotericin B.
di Martino L; Davidson RN; Giacchino R; Scotti S; Raimondi F; Castagnola E; Tasso L; Cascio A; Gradoni L; Gramiccia M; Pettoello-Mantovani M; Bryceson AD
J Pediatr; 1997 Aug; 131(2):271-7. PubMed ID: 9290615
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
[TBL] [Abstract][Full Text] [Related]
8. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
9. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2536. PubMed ID: 24392166
[TBL] [Abstract][Full Text] [Related]
11. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2603. PubMed ID: 24392168
[TBL] [Abstract][Full Text] [Related]
12. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
Croft SL; Davidson RN; Thornton EA
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
[TBL] [Abstract][Full Text] [Related]
14. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
[TBL] [Abstract][Full Text] [Related]
15. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
16. [A multifocal form of cutaneous leishmaniasis caused by Leishmania infantum in an immunocompetent child treated with a short course of liposomal amphotericin B].
Taquin H; Chiaverini C; Marty P; Lacour JP
Ann Dermatol Venereol; 2016 Oct; 143(10):622-624. PubMed ID: 27292718
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
20. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum.
Oliva G; Gradoni L; Ciaramella P; De Luna R; Cortese L; Orsini S; Davidson RN; Persechino A
J Antimicrob Chemother; 1995 Dec; 36(6):1013-9. PubMed ID: 8821600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
